Prevalence of hemoglobin abnormalities in an apparently healthy population in Benin

Zohoun, Alban; Agbodande, Tatiana Baglo; Zohoun, Lutécia; Anani, Ludovic

doi:10.1016/j.htct.2019.06.005

Cited by 7 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To reduce SCD related morbidity and mortality, the therapies discussed in this review should be implemented in synergy with ensuring the uptake and sustainability of resource intensive EBIs [ 84 – 86 ]. Future studies undertaken in LMICs that face suboptimal infrastructure and resources, must employ implementation research methodology whilst engaging key stakeholders (providers and patients) and integrate findings from implementation outcome assessment into evidence-based practice for SCD management.…”

Section: Discussionmentioning

confidence: 99%

Evidence-based interventions implemented in low-and middle-income countries for sickle cell disease management: A systematic review of randomized controlled trials

et al. 2021

View full text Add to dashboard Cite

Background Despite ~90% of sickle cell disease (SCD) occurring in low-and middle-income countries (LMICs), the vast majority of people are not receiving evidence-based interventions (EBIs) to reduce SCD-related adverse outcomes and mortality, and data on implementation research outcomes (IROs) and SCD is limited. This study aims to synthesize available data on EBIs for SCD and assess IROs. Methods We conducted a systematic review of RCTs reporting on EBIs for SCD management implemented in LMICs. We identified articles from PubMed/Medline, Global Health, PubMed Central, Embase, Web of Science medical subject heading (MeSH and Emtree) and keywords, published from inception through February 23, 2020, and conducted an updated search through December 24, 2020. We provide intervention characteristics for each study, EBI impact on SCD, and evidence of reporting on IROs. Main results 29 RCTs were analyzed. EBIs identified included disease modifying agents, supportive care agents/analgesics, anti-malarials, systemic treatments, patient/ provider education, and nutritional supplements. Studies using disease modifying agents, nutritional supplements, and anti-malarials reported improvements in pain crisis, hospitalization, children’s growth and reduction in severity and prevalence of malaria. Two studies reported on the sustainability of supplementary arginine, citrulline, and daily chloroquine and hydroxyurea for SCD patients. Only 13 studies (44.8%) provided descriptions that captured at least three of the eight IROs. There was limited reporting of acceptability, feasibility, fidelity, cost and sustainability. Conclusion EBIs are effective for SCD management in LMICs; however, measurement of IROs is scarce. Future research should focus on penetration of EBIs to inform evidence-based practice and sustainability in the context of LMICs. Clinical trial registration This review is registered in PROSPERO #CRD42020167289.

show abstract

Section: Discussionmentioning

confidence: 99%

Evidence-based interventions implemented in low-and middle-income countries for sickle cell disease management: A systematic review of randomized controlled trials

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This publication inspired in me to comment on this important public health topic that dangerously gnaws at our societies in sub-Saharan Africa. In Benin, recent data estimate a 22.3% prevalence of sickle cell trait (hemoglobin S) and a 10.21% prevalence of hemoglobin C, and 4% of the population would be affected by hemoglobin SS homozygosity and hemoglobin SC double heterozygosity (Rahimy et al, 2009;Zohoun et al, 2020). With an estimated population of 13 million, in Benin, the absolute number of the population concerned with this problem would be estimated to be more than 4 million.…”

Section: Current Situation In Beninmentioning

confidence: 99%

Commentary: Rehabilitation: a key service, yet highly underused, in the management of young patients with sickle cell disease after stroke in DR of Congo

Kossi

2024

Front. Stroke

View full text Add to dashboard Cite

“…Figure 3. Global and regional prevalence a of sickle cell trait in Africa [22][23][24]41], Europe [26,28,42], India [30][31][32][33][34][35][43][44][45], the Middle East [36][37][38][39]46,47], and South America/the Caribbean [48,49]. a Within each region, the prevalence was estimated using a binomial normal model, which assumed a binomial distribution for the individual studies with a mean value drawn from a normal distribution for a regional/global value.…”

Section: Quantitative Meta-analysis Of Prevalence and Birth Prevalencementioning

confidence: 99%

Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection

Colombatti,

Hegemann,

Medici

et al. 2023

JCM

View full text Add to dashboard Cite

Sickle cell disease (SCD) is an inherited monogenic disorder with high prevalence throughout sub-Saharan Africa, the Mediterranean basin, the Middle East, and India. Sources of SCD epidemiology remain scarce and fragmented. A systematic literature review (SLR) to identify peer-reviewed studies on SCD epidemiology was performed, with a search of bibliographic databases and key conference proceedings from 1 January 2010 to 25 March 2022 (congress abstracts after 2018). The SLR followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Meta-analyses, using a binomial normal random-effects model, were performed to estimate global and regional prevalence and birth prevalence. Of 1770 journal articles and 468 abstracts screened, 115 publications met the inclusion criteria. Prevalence was highest in Africa (~800/100,000), followed by the Middle East (~200/100,000) and India (~100/100,000), in contrast to ~30/100,000 in Europe. Birth prevalence was highest in Africa (~1000/100,000) and lowest in North America (~50/100,000) and Europe (~30/100,000). This SLR confirmed that sub-Saharan and North-East Africa, India, the Middle East, and the Caribbean islands are global SCD hotspots. Publications including mortality data were sparse, and no conclusions could be drawn about mortality. The identified data were limited due to gaps in the published literature for large parts of the world population; the inconsistent reporting of SCD genotypes, diagnostic criteria, and settings; and a sparsity of peer-reviewed publications from countries with assumed high prevalence. This SLR demonstrated a lack of systematic knowledge and a need to provide uniform data collection on SCD prevalence and mortality.

show abstract

Prevalence of hemoglobin abnormalities in an apparently healthy population in Benin

Cited by 7 publications

References 11 publications

Evidence-based interventions implemented in low-and middle-income countries for sickle cell disease management: A systematic review of randomized controlled trials

Evidence-based interventions implemented in low-and middle-income countries for sickle cell disease management: A systematic review of randomized controlled trials

Commentary: Rehabilitation: a key service, yet highly underused, in the management of young patients with sickle cell disease after stroke in DR of Congo

Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection

Contact Info

Product

Resources

About